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As we move into the era of exome and whole-genome 
sequencing and witness a concurrent explosion in 
genomic data, concerns about related biotechnology 
patents must also shift accordingly. These are complex 
issues that are in a state of flux, and we find ourselves at 
an especially critical juncture given the US Supreme 
Court’s recent treatment of several high-profile bio tech-
nology cases. Here, we discuss recent developments in 
US patent law and the most pressing issues on the 
horizon, including pivotal issues surrounding the topic of 
patenting in genetics and biotechnology in the US. We 
particularly address some of the neglected or seemingly 
arcane points that nevertheless are critical to the 
researcher, medical practitioner, scientist, or indeed any-
one seeking informed opinions about patent protec tion 
of new biotechnologies and genetic technologies. Striking 
the appropriate balance between intellectual property 
protection and public benefit is essential to promoting 
advances in the field.
The term ‘gene patent’ itself is ambiguous, and this 
term has been used loosely in the media to encompass a 
wide variety of patents related to genetics. Patents 
typically contain multiple claims in various forms, and 
each claim in a patent may stand or fall independently of 
the others. The subject matter claimed can be a tangible 
product (such as a DNA molecule) or a process indicated 
by gerunds (for example, ‘constructing’, ‘connecting’, or 
‘sequencing’) that outline the steps of the method.
Both product and method claims are found in gene-
related patents. Understanding the different claims en-
com passed by the imprecise term ‘gene patent’ is critical to 
the proper interpretation and application of patent law as 
we seek to optimally promote the development of genetic 
medicine. Because patent law is complicated (see Box 1 for 
a brief summary), the popular media under standably tends 
to avoid going into such differences in their attempts to 
simplify headlines about the topic [1,2]. The Supreme 
Court has recently cast serious doubt on broad method 
claims related to genes - but not on product claims.
A claim directed to ‘isolated DNA’ covers a single type 
of molecule, such as a PCR product, usually referring to a 
specific DNA sequence. It does not cover the sequence 
itself, as many professionals seem to believe. Thus, the 
patent holder is legally entitled to exclude others from 
making or using only that isolated DNA, based on that 
particular claim. Depending on how the claim is worded, 
the court may interpret it to cover isolated molecules 
with additional sequences that flank the named sequence 
(such as in a purified plasmid or other vector), but under 
no circumstances should a claim to isolated DNA 
preempt others from using its corresponding sequence as 
it exists within genomic DNA. That is the whole point of 
using the word ‘isolated’ - to clarify that the natural 
occurrence of that sequence is not what is claimed in the 
patent, but rather the physical molecule.
For scientists and physicians, the critical question should 
be whether any given patent stands in the way of their 
work. Isolated DNA claims are becoming less relevant to 
medical diagnostics, because sequencing a patient’s DNA 
with modern (next-generation) technology is unlikely to 
infringe any product claim directed to an isolated DNA 
molecule. Thus, in a new genomic era, it is appropriate to 
refocus on broad method claims that have greater potential 
to affect the practice of medicine and medical research.
The Myriad case: why it is important and where it 
stands today
As with many gene patents, the gene patent case 
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(‘Myriad’) [3] included both method and product claims, 
which are affected differently by recent court decisions. 
On 20 March 2012, a unanimous Supreme Court held in 
Prometheus v. Mayo (‘Prometheus’) [4] that Prometheus 
Laboratories’ claims to methods of optimizing the dosage 
of drugs to treat gastrointestinal autoimmune diseases do 
not qualify as patentable subject matter under section 101 
of the Patent Act (the section that specifically deals with 
what types of subject matter are eligible for patenting) [5].
Prometheus itself is not a gene patent case but has 
important implications for gene patents, especially claims 
of the method type. Thus, shortly thereafter, the Supreme 
Court issued a ‘GVR order’ for the Myriad case [3] in light 
of their decision in Prometheus. A GVR order means that 
in one swift motion, the Supreme Court (1) granted review 
of the Myriad case, (2) vacated the decision of the court of 
appeals below, and (3) remanded the case back to the court 
of appeals for further review in light of the new Supreme 
Court decision in Prometheus. The justices apparently 
believe that the court of appeals might find something 
relevant to the Myriad case within their analysis of 
Prometheus. Unfortunately, the patent practi tioner 
community is having a difficult time figuring out what that 
might be, and therefore a large number of biotechnology 
patents currently stand in limbo [6]. One reporter wrote, 
‘It is apparently possible to split legal hairs endlessly over 
whether DNA is or is not patentable, and these patent 
claims will certainly be fought to the bitter end, as they are 
a crucial test case for future decisions’ [1].
The Court of Appeals for the Federal Circuit (CAFC) is 
the US court that hears first appeals on all US patent 
cases. In March 2010, in the Myriad case, a Federal 
District Court judge invalidated all of Myriad Genetics’ 
challenged gene patents. Myriad appealed to the CAFC, 
and in July 2011 the CAFC announced its decision. That 
decision partially reversed that of the District Court on 
many of Myriad’s challenged ‘isolated DNA’ product 
claims, finding them to encompass legitimately patentable 
subject matter under section 101 of the Patent Act.
But the plaintiffs (the patent challengers) actually won 
some very important aspects of the case at the CAFC level 
the first time. Although the CAFC decision upheld many 
of the product claims at issue, it also affirmed the lower 
court’s invalidation of Myriad’s broad method claims. This 
part of the decision has received little fanfare. A closer 
look suggests that disproportionately heightened public 
concern over isolated DNA product claims, although 
understandable, is misplaced and that we should keep our 
eye on the right ball - in this case, the outcome of 
deliberations regarding the eligibility of the method claims.
A representative method claim from Myriad’s US 
Patent No. 6,033,857 is:
Claim 1: A method for identifying a mutant BRCA2 
nucleotide sequence in a suspected mutant BRCA2 
allele which comprises comparing the nucleotide 
sequence of the suspected mutant BRCA2 allele 
with the wild-type BRCA2 nucleotide sequence, 
where in a difference between the suspected mutant 
and the wild-type sequences identifies a mutant 
BRCA2 nucleotide sequence. [our emphasis]
The CAFC decision rejected these method claims to 
comparing BRCA2 sequences on the basis that they 
Box 1. A US patent law primer
US patent law requires that a number of different complex requirements be met before a patent is granted, and the validity of an issued 
patent may be challenged thereafter on any of the same grounds. The requirements are codified in sections 101, 102, 103, and 112 of USC 
Title 35, also known as the Patent Act. Section 101 addresses only what types of subject matter are eligible for patenting [5]; the other 
sections address issues of novelty, obviousness, and sufficiency of the accompanying descriptions for fully enabling others in the field to 
make and use the invention or discovery.
Historically, section 101 has been construed very broadly by the Supreme Court and the US Patent and Trademark Office to include 
‘anything under the sun made by man’ and the other sections have been applied more stringently to filter out subject matter that is 
unsuitable for patenting (for example, products of nature and abstract concepts). The distinctions between the requirements of these four 
sections of the Patent Act are the source of much confusion for many non-patent professionals, including scientists, engineers, physicians, 
and even lawyers and judges who are not specialists in patent law.
A US patent is enforceable only in its home country. However, international agreements such as the Patent Cooperation Treaty provide 
some degree of uniformity between the patent laws of various countries [20]. These agreements also provide for easier pursuit of patent 
protection on a new technology in multiple jurisdictions. Nevertheless, the courts of each country must interpret the particular law of their 
own jurisdiction, and all of these factors combined yield different end results for patent challenges across the world [21,22].
The Court of Appeals for the Federal Circuit (CAFC) is the highest patent specialist court in the US. In fact, this court of appeals has unique 
authority among all the US courts of appeals. Its decisions are binding precedents throughout the US on patent law matters, whereas the 
other courts of appeals are binding only for their own geographic jurisdictions. Thus, the only superseding authorities are the Supreme 
Court and Congress. Furthermore, because Supreme Court review is discretionary, CAFC decisions are often the final word on patent law 
matters [23].
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recite ‘nothing more than abstract mental steps’. The 
Supreme Court has previously said that the only 
recognized exceptions for patent eligibility, at the most 
basic level (section 101), are ‘laws of nature, physical 
phenomena, and abstract ideas’ [7]. Further guidance for 
determining when claims cover abstract ideas is scant, 
but methods comprising purely mental steps such as 
comparing have consistently been found to encompass 
abstract ideas [8].
When the Supreme Court decided Prometheus, they 
said that the claims in dispute, which describe a process 
(or method) of adjusting drug dosage based on metabolite 
levels, essentially monopolized laws of nature. The rele-
vant laws of nature, according to the court, are the 
‘relationships between concentrations of certain metabo-
lites in the blood and the likelihood that a dosage of a 
thiopurine drug will prove ineffective or cause harm’. 
They asked, ‘do the patent claims add enough to their 
state ments of the correlations to allow the processes they 
describe to qualify as patent-eligible processes that apply 
natural laws?’ [9].
Their unanimous answer was that in this case, the 
aspects of the claims related to application of the law of 
nature were ‘not enough’. Supreme Court decisions are 
supposed to guide the lower judiciary and lawyers’ 
expectations for subsequent cases, but it is unclear just 
how to determine whether similar method claims might 
pass muster under this analysis. That is, how can the 
Supreme Court’s reasoning be applied to other patents to 
reasonably predict how much is enough? Without further 
guidance from the Supreme Court, method claims 
regard ing specific genes are now in a tenuous position.
Moreover, the Supreme Court’s analysis discusses that 
the steps of the claimed process are ‘well understood, 
routine, conventional activity’. This sounds to the patent 
community suspiciously close to a line of argument about 
novelty or obviousness rather than about proper subject 
matter eligibility [10]. Alternatively, it might suggest that 
the Supreme Court is insisting that novelty and obvious-
ness have some relevance to subject matter eligibility. The 
CAFC has now asked the parties to submit supplemental 
briefs explaining how the Prometheus ruling applies to 
the Myriad claims.
isolated DnA molecules
Although broad method claims may have the potential 
for widespread effects on the genetic community, patent 
claims on any particular isolated DNA molecule, although 
common, are becoming less relevant in diagnostics because 
of advancing technology. Next-generation sequencing 
platforms generally avoid the need to isolate any 
particular DNA molecule. It is therefore unlikely that 
sequencing would infringe claims requiring DNA 
isolation, including a claim to an isolated DNA having 
any particular sequence. We are not the first to propose 
that whole-genome sequencing probably infringes patents 
involving genetic technologies to a lesser extent than 
widespread beliefs might suggest [11].
There is further reason to be less concerned about 
product claims that focus on isolated DNA. Owing to the 
dissemination of genetic knowledge and requirements of 
latter sections of the Patent Act (Box 1), it is becoming 
more difficult to receive allowance from the patent office 
on DNA claims. If the sequence has been published, such 
as in the reference human genome, the corresponding 
DNA molecules become far less novel and non-obvious; 
novelty and non-obviousness are both additional require-
ments for patenting. Moreover, the patents having DNA 
claims in the Myriad case will begin to expire in 2014, 
and many other patents covering DNA molecules with 
naturally occurring sequences will likewise expire in the 
next decade.
The Supreme Court has stated that Congress intended 
patentable subject matter to ‘include anything under the 
sun that is made by man’ [12], and it is indisputable that a 
PCR product fits that description. A gene as it exists in 
nature, by contrast, is certainly not ‘made by man’, and 
enforcement of the Myriad method claim discussed above 
could arguably monopolize the BRCA2 gene to some 
extent. To be fair, holders of such gene patents have 
generally not used them against basic research activities. 
One only has to search ‘BRCA’ in literature databases to 
realize that Myriad has not asserted its patents against 
publicly funded basic research endeavors. Nevertheless, 
these claims have been asserted in the setting of clinical 
research for a fee by Myriad Genetics, and indiscriminate 
assertion of such patents is always a possibility.
Although granting patent protection related to a naturally 
occurring gene is both fundamentally problem atic to 
some and increasingly dubious from the stand point of 
novelty and non-obviousness to others, the development 
of new, non-natural DNA sequences through synthetic 
biology is a field in which full public disclosure in patent 
applications is highly desirable and warrants rewarding 
the inventor with a monopoly. So for synthetic DNA 
technology, it should be permissible to claim a DNA 
having a truly novel sequence, because there is no DNA 
with that sequence found in nature.
More medical diagnostic claims: mental steps and 
abstract concepts
The Myriad case has received the most attention in 
recent popular media, and Prometheus is now running a 
close second. But there is a third relevant contemporary 
biotechnology case involving diagnostic methods claims 
in which the challenge is focused solely on whether the 
subject matter is patent eligible. The common thread 
among these cases is the primary issue argued - that the 
Dobson and Evans Genome Biology 2012, 13:161 
http://genomebiology.com/2012/13/6/161
Page 3 of 6
methods claims are ‘abstract’. A judicially created 
doctrine forbids patenting of abstract principles [8].
It can be very challenging for the courts to determine 
where to draw the line between a purely abstract idea 
that effectively ‘preempts broadly the use of any natural 
correlation’ and a patentable application of that concept, 
such as a specific biochemical test [13]. For example, 
well-known methods used to administer prescription 
drugs and test blood have been found to involve ‘trans-
formations’ of body chemistry, which moves the method 
out of the abstract category [14].
Classen Immunotherapies, Inc. v. Biogen Idec (‘Classen’), 
like Prometheus, is also not specifically about gene 
patents but involves conceptually similar method claims 
[13]. In this case, the Classen patents cover methods for 
correlating vaccination schedules with later development 
of immune-mediated diseases. Some of the claims are 
very broad. In fact, Judge Moore dissented from the other 
two judges in the ruling, and she read the claims to 
preempt the scientific method itself. The basic steps of 
the method are:
1 screening information on immunization schedules and 
the occurrence of chronic immune-mediated disease,
2 comparing the results from different vaccination 
schedules and identifying the lower risk schedule, and
3 administering the vaccine on that lower risk schedule.
The CAFC invalidated some claims that only include 
steps of screening and comparing vaccination schedules 
for correlations with later development of immune-
mediated disorders. However, once again the ‘adminis-
tering’ step takes the claims out of the abstract category 
according to the majority of judges. The court allowed 
claims that included an additional step of administering 
vaccinations, solely because the additional administering 
step transforms the method from an abstract concept to a 
patent-eligible application of that concept. The striking 
effect, as noted by the CAFC, is that a physician might 
infringe merely by reviewing the literature and then 
vaccinating on the schedule that seems best to him or her.
A common theme in earlier higher court decisions is 
that a method claim solely comprising mental steps such 
as reviewing, comparing, analyzing, screening, selecting, 
and determining will not stand as eligible to be patented 
because it is abstract. And even if the claim includes 
additional non-abstract steps, such as in Classen and 
Prometheus, it may not stand if it does not meet the 
requirements of the rest of the Patent Act, such as novelty 
and non-obviousness.
novelty and non-obviousness
Novelty is a question of whether the technology is really 
new. Obviousness may be found where the ‘subject 
matter as a whole… was obvious to one of ordinary skill 
in the art…’ at the time of invention [15]. This is usually 
an inquiry that involves having experts from each party 
explain why their party is correct to advise the court on 
how obvious they think the invention was. This is also a 
difficult inquiry, but at least the courts are instructed to 
consider a number of better-defined criteria that come 
from precedential cases (called Graham factors).
The CAFC and many patent practitioners have ex-
pressed frustration over the recent trend of increased 
reliance on subject matter eligibility arguments (such as 
whether the patent claim is abstract) rather than novelty 
or obviousness arguments [16]. The patent community 
has long struggled to properly convey this important 
concept - the sections that follow section 101 (Box 1) are 
meant to provide the real teeth for eliminating objection-
able patents. For example, according to a precedential 
patent office case (affirmed by the CAFC), a claim to the 
human DNA for protein X is obvious if the mouse DNA 
for protein X was already known in the literature and 
there was good reason to believe that homologous human 
DNA existed [17]. The Supreme Court analysis of 
Prometheus sounds disturbingly similar to an obviousness 
argument to many patent practitioners [10]. Thus, it is 
not clear that the present Supreme Court fully under-
stands the distinctions between section 101 and the sec-
tions that follow it, which have historically been preferred 
over section 101 for finding problematic subject matter 
unpatentable.
A general tenet of US law holds that, where multiple 
arguments are presented, the court focuses on the 
clearest and most determinative argument that can 
decide the case. In the interest of judiciary efficiency, the 
court does not consider other more difficult issues. It is 
much easier for judges to explain a decision that 
invalidates a claim based on arguments that the invention 
is obvious or because it has already been described in the 
literature than decisions based on other issues. The 
Supreme Court and CAFC both previously tended towards 
that strategy, to avoid addressing the more difficult and 
more broadly applicable section 101 subject matter 
question that is designated to Congress. And Congress 
does act on that responsibility occasionally  - the 2011 
America Invents Act includes a prohibition on patents 
covering human organisms [18].
The arguments available under the latter sections of the 
Patent Act are often much stronger and clearer. In fact, in 
Classen the CAFC took the unusual additional step of 
outlining exactly how all of the remaining ‘administering’ 
claims would have been successfully defeated under 
patent rules in other parts of the Act. The most glaring 
issue was that the literature had completely described a 
system for comparing vaccination schedules over a 
decade before Classen tried to patent the method, so the 
invention lacked novelty and would therefore be 
invalidated if challenged on that theory.
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In addition, in Classen the CAFC panel specifically 
admonishes litigants over the lack of arguments based on 
other parts of the Patent Act, in three separate opinions. 
All three judges suggest to varying degrees that all of 
Classen’s claims would be invalid if properly challenged. 
Indeed, even in the Myriad decision the CAFC suggests 
that arguments under the more stringent sections of the 
Patent Act would have a much better chance of defeating 
even the isolated DNA claims.
other important factors to consider
Each claim in a patent may stand or fall independently of 
the other claims. Thus, each claim in a patent must be 
analyzed separately to determine what it encompasses. 
The examiners at the patent office are charged to do the 
same analysis before granting a patent, but as with all 
human activity, it is inevitable that examiners make 
mistakes. A safeguard lies in the fact that US patents can 
be challenged after they are granted on most of the same 
requirements as for examination.
Secrecy is sometimes an alternative to patenting, but 
one that conveys less benefit to the public than the 
protection of technology investment through granting of 
patents. The public value of the patent system lies in the 
innovator’s duty to fully disclose the patented discovery 
or invention to the public in return for the limited 
monopoly granted by a patent. In addition, patents serve 
to provide security to potential investors in new 
bio technologies.
The possibility that privately funded ventures will 
increasingly resort to secrecy to protect new DNA tech-
nologies is substantial and could frustrate progress 
overall. Some types of technology will not be feasible to 
protect through secrecy, and those potential ventures 
may simply be abandoned for lack of confidence in the 
ability to protect investment. Thus, it can be dangerous 
to take an all-or-none approach to the patent system and 
its effects on progress in medical science. Licensing 
practices are also important in limiting or exacerbating 
negative effects of patents. In particular, those involved in 
technology transfer of federally funded university 
inventions should be careful in appropriate circumstances 
to maintain policies against exclusive licensing ([19] and 
Catherine Innes, personal communication).
History is full of examples in which existing law could 
not keep up with what was happening on the ground. The 
Homestead Act of 1862 was an official acknowledgement 
by the US government of the pioneers’ land claims, but 
people were moving west, staking those claims, and 
occupying the land before the Homestead Act anyway. 
Likewise, we are probably witnessing significant patent 
infringement (with regard to all of the now-tenuous 
method claims) owing to the reality of next-generation 
sequencing and its widespread adoption. Science forges 
ahead despite the more broadly drafted method claims, 
including the myriad large-scale sequencing efforts (pun 
intended) currently underway at multiple centers. Such 
efforts are potentially infringing many method patents 
that may or may not withstand legal challenge according 
to the Supreme Court’s fuzzy analysis of Prometheus. 
Meanwhile, stakeholders will benefit from considering 
what activities are truly preempted by specific types of 
patent claims.
Finally, it is important to remember the central intent 
of the US patent system, which is not primarily as a 
generator of revenue but rather to ‘promote the progress 
of science and useful arts’. Broad patent claims covering 
diagnostic methods should be a greater concern for 
proponents of unencumbered scientific exploration and 
medicine than the ‘isolated DNA’ product claims more 
commonly associated with the term ‘gene patent’. The 
medical and genetic communities should pay attention to 
what really matters.
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